- COVID-19 UPDATES
- STRONGBOX DATA SOLUTIONS
- FUJIFILM PRODUCTS
- QSTAR TECHNOLOGIES
- ABOUT US
June 3, 2020
By Kara Buzzeo
“These are unprecedented times,” a phrase we all have heard so many times, we might have even started saying it in our sleep. Throughout these unprecedented times, Fujifilm has made a commitment to doing its part to combat the uncertainty, chaos, and panic caused by COVID-19.
On March 30th, just 20 days after the World Health Organization declared a global pandemic, Fujifilm started its phase III clinical trials in Japan, to evaluate the safety and efficacy of influenza antiviral drug “Avigan”* for patients with COVID-19.
Since then, FUJIFILM Pharmaceuticals U.S.A, Inc. initiated a phase II clinical trial of Avigan in the U.S. for patients with COVID-19. Patients will be enrolled in the study at three Massachusetts area hospitals.
FUJIFILM Recording Media U.S.A, Inc. (FRMU) has been able to assist nearby hospitals by providing logistics support during this time, storing the PPE in secure, safe locations.
One of the most outstanding moments during this time of crisis was our employees’ desire to contribute. Inspired by acts of kindness seen around the world and within the organization, FRMU employees wanted to make sure that they were doing their part to help their communities. At the Bedford manufacturing plant, employees took the initiative to manufacture face shields that were then donated to hospitals in Massachusetts, New Hampshire, and Washington D.C. Normally, every year FRMU hosts a kick-off meeting where employee appreciation gifts are given out, however this year, the money was allocated to Amazing Grace Food Pantry in Middletown, CT to aid in helping families put food on the table during this difficult time.
Through collaboration, technology, and our collective expertise, we will continue to work towards improving human health and helping bring the pandemic to an end.
* Avigan is not FDA approved in the United States.